Supportive Care in Cancer

, Volume 21, Issue 6, pp 1561–1568

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

  • I. N. Olver
  • P. Grimison
  • M. Chatfield
  • M. R. Stockler
  • G. C. Toner
  • V. Gebski
  • R. Harrup
  • C. Underhill
  • G. Kichenadasse
  • N. Singhal
  • I. D. Davis
  • A. Boland
  • A. McDonald
  • D. Thomson
  • for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Original Article

DOI: 10.1007/s00520-012-1696-0

Cite this article as:
Olver, I.N., Grimison, P., Chatfield, M. et al. Support Care Cancer (2013) 21: 1561. doi:10.1007/s00520-012-1696-0

Abstract

Purpose

The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy.

Methods

In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1.

Results

Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27 %, respectively. The efficacy was maintained in all cycles with over 80 % of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68 % episodes) than on days 1 to 3 (32 % episodes). Over any 24-h period, 49 % of patients with emesis reported no more than two episodes, and 62 % of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported.

Conclusion

Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting.

Keywords

AprepitantDexamethasone5Hydroxytryptamine3 receptor antagonist5-day cisplatinAntiemeticGerm cell tumors

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • I. N. Olver
    • 1
  • P. Grimison
    • 2
  • M. Chatfield
    • 3
  • M. R. Stockler
    • 2
    • 3
  • G. C. Toner
    • 4
  • V. Gebski
    • 3
  • R. Harrup
    • 5
  • C. Underhill
    • 6
  • G. Kichenadasse
    • 7
  • N. Singhal
    • 8
  • I. D. Davis
    • 9
  • A. Boland
    • 3
  • A. McDonald
    • 3
  • D. Thomson
    • 10
  • for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  1. 1.Sydney Medical School, CEO Cancer Council AustraliaSydneyAustralia
  2. 2.Sydney Cancer CentreSydneyAustralia
  3. 3.NHMRC Clinical Trials CentreUniversity of SydneySydneyAustralia
  4. 4.Peter MacCallum Cancer CentreEast Melbourne and University of MelbourneMelbourneAustralia
  5. 5.Royal Hobart HospitalHobartAustralia
  6. 6.Border Medical OncologyAlburyAustralia
  7. 7.Flinders Medical CentreFlinders UniversityAdelaideAustralia
  8. 8.Royal Adelaide HospitalAdelaideAustralia
  9. 9.Ludwig Institute for Cancer Research, Austin HealthMelbourneAustralia
  10. 10.Princess Alexandra HospitalBrisbaneAustralia